Division of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, United States.
Front Immunol. 2019 Mar 6;10:309. doi: 10.3389/fimmu.2019.00309. eCollection 2019.
Acute graft-vs.-host disease (GVHD) limits the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT), a main therapy to treat various hematological disorders. Despite rapid progress in understanding GVHD pathogenesis, broad immunosuppressive agents are most often used to prevent and remain the first line of therapy to treat GVHD. Strategies enhancing immune tolerance in allo-HSCT would permit reductions in immunosuppressant use and their associated undesirable side effects. In this review, we discuss the mechanisms responsible for GVHD and advancement in strategies to achieve immune balance and tolerance thereby avoiding GVHD and its complications.
急性移植物抗宿主病（GVHD）限制了异基因造血干细胞移植（allo-HSCT）的疗效，allo-HSCT 是治疗各种血液系统疾病的主要方法。尽管人们对 GVHD 发病机制的理解取得了快速进展，但广泛使用免疫抑制剂来预防和仍然是治疗 GVHD 的一线疗法。增强 allo-HSCT 中免疫耐受的策略可以减少免疫抑制剂的使用及其相关的不良副作用。在这篇综述中，我们讨论了导致 GVHD 的机制以及实现免疫平衡和耐受的策略的进展，从而避免 GVHD 及其并发症。
